ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,037.59
1.06%
Dow Jones
43,325.80
0.07%
US Dollar vs MXN
20.2171
-0.01%
Brent Oil
73.045
0.21%
Bitcoin
94,670.62
-1.06%
Pepperstone
Advertisement
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Prime Medicine Inc (PRME) Cotización

Prime Medicine Inc

Prime Medicine Inc (PRME)

Prim SA
Prim SA
Prim SA
Prim SA
Prime Drink Group Corp
2.94
0.18
(6.52%)
Cerrado 27 Diciembre 3:00PM
Delayed by 15 minutes
2.92
-0.02
(-0.68%)
Fuera de horario: 6:27PM
Delayed by 15 minutes

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Estadísticas y detalles clave

Último Precio
2.92
Postura de Compra
2.77
Postura de Venta
2.90
Volume Operado de la Acción
877,589
2.69 Rango del Día 2.94
2.56 Rango de 52 semanas 9.80
Capitalización de Mercado [m]
382.99M
Precio Anterior
2.76
Precio de Apertura
2.74
Hora
1
@
2.91
Última hora de negociación
Volumen financiero
US$ 2,490,470
Precio Promedio Ponderado
2.8379
Volumen promedio (3 m)
1,200,930
Acciones en circulación
131,160,842
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-1.95
Beneficio por acción (BPA)
-1.51
turnover
-
Beneficio neto
-198.13M

Acerca de Prime Medicine Inc

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome a... Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs. Mostrar más

Sector
Biological Pds,ex Diagnstics
Industria
Biological Pds,ex Diagnstics
Sitio web
www.primemedicine.com
Sede
Wilmington, Delaware, USA
Fundado
-
Prime Medicine Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker PRME. The last closing price for Prime Medicine was US$2.76. Over the last year, Prime Medicine shares have traded in a share price range of US$ 2.56 to US$ 9.80.

Prime Medicine currently has 131,160,842 shares in issue. The market capitalisation of Prime Medicine is US$362 million. Prime Medicine has a price to earnings ratio (PE ratio) of -1.95.

PRME Últimas noticias

Más noticias

Form EFFECT - Notice of Effectiveness

22 Diciembre 2024
Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933

13 Diciembre 2024
Edgar (US Regulatory)

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

22 Noviembre 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

12 Noviembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

12 Noviembre 2024
Edgar (US Regulatory)

Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates

-- Presented initial in vivo data for universal liver-targeted LNP and Wilson’s Disease program at ESGCT; initiated IND-enabling activities for Wilson’s Disease program in 4Q 2024 and remains on...

12 Noviembre 2024
GlobeNewswire Inc.

Prime Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...

06 Noviembre 2024
GlobeNewswire Inc.

Form 8-K - Current report

24 Octubre 2024
Edgar (US Regulatory)

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Delivery of Prime Editors with a proprietary, universal liver-targeted LNP was well tolerated, with no safety concerns or detectable off-target edits observed across multiple preclinical studies...

24 Octubre 2024
GlobeNewswire Inc.

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings

-- On-track to initiate IND-enabling activities for Wilson’s Disease program in 4Q 2024, with IND or CTA filing expected in 1H 2026 -- CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Prime...

15 Octubre 2024
GlobeNewswire Inc.
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.186.569343065692.743.052.5614024272.83826626CS
4-0.4-12.04819277113.323.5152.5612645263.02182771CS
12-0.51-14.86880466473.434.712.5612009303.52266638CS
26-2.92-505.846.752.5612245233.93054229CS
52-6.5-69.00212314239.429.82.569923545.02525689CS
156-16.05-84.607274644218.9721.73012.566486287.2878939CS
260-16.05-84.607274644218.9721.73012.566486287.2878939CS

PRME - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Prime Medicine?
El precio actual de las acciones de Prime Medicine es US$ 2.92
¿Cuántas acciones de Prime Medicine están en circulación?
Prime Medicine tiene 131,160,842 acciones en circulación
¿Cuál es la capitalización de mercado de Prime Medicine?
La capitalización de mercado de Prime Medicine es USD 362M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Prime Medicine?
Prime Medicine ha negociado en un rango de US$ 2.56 a US$ 9.80 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Prime Medicine?
El ratio precio/beneficio de Prime Medicine es -1.95
¿Cuál es la moneda de reporte de Prime Medicine?
Prime Medicine presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de Prime Medicine?
El último beneficio anual de Prime Medicine es USD -198.13M
¿Cuál es la dirección registrada de Prime Medicine?
La dirección registrada de Prime Medicine es CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Prime Medicine?
La dirección del sitio web de Prime Medicine es www.primemedicine.com
¿En qué sector industrial opera Prime Medicine?
Prime Medicine opera en el sector BIOLOGICAL PDS,EX DIAGNSTICS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
AIREreAlpha Tech Corporation
US$ 3.5701
(160.59%)
130.88M
SPRCSciSparc Ltd
US$ 0.50
(126.04%)
239.51M
ZCARZoomcar Holdings Inc
US$ 2.80
(95.80%)
60.3M
MGIHMillennium Group International Holdings Ltd
US$ 2.9698
(94.10%)
75.35M
SKKSKK Holdings Limited
US$ 1.35
(80.48%)
52.11M
LNKSLinkers Industries Ltd
US$ 3.295
(-65.64%)
3.65M
GTIGraphjet Technology
US$ 0.3354
(-45.02%)
22.44M
BAOSBaosheng Media Group Holdings Ltd
US$ 4.3979
(-38.06%)
1.97M
NEUPNeuphoria Therapeutics Inc
US$ 4.34
(-34.54%)
599.97k
SVRESaverOne 2014 Ltd
US$ 1.0501
(-30.46%)
1.36M
XTIAXTI Aerospace Inc
US$ 0.0398
(1.53%)
270.76M
SPRCSciSparc Ltd
US$ 0.50
(126.04%)
239.51M
COEPCoeptis Therapeutics Holdings Inc
US$ 0.213249
(50.18%)
205.2M
RGTIRigetti Computing Inc
US$ 15.445
(36.08%)
204.3M
SMXSMX Security Matters Public Company
US$ 0.3303
(51.51%)
172.17M

PRME Discussion

Ver más
Monksdream Monksdream 5 días hace
PRME, under $

👍️0
PonkenPlonken PonkenPlonken 4 semanas hace
Super super undervalued..
Recent PSTX - Roche deal should have made this run? Atleast given it also recently partnered with BMS... makes zero sense.
Is a clear validation CRISPR genome editing is hot in cancer cell therapy.
Waiting for a sign....
👍️0
Monksdream Monksdream 2 meses hace
PRME under $5
👍️0
Monksdream Monksdream 3 meses hace
PRME new 52 week low
👍️0
Invest-in-America Invest-in-America 3 meses hace
PRME: Glad I grabbed a chunk of THIS ONE!!!!
👍️0
PonkenPlonken PonkenPlonken 3 meses hace
"Under the terms of the agreement, Prime Medicine will receive a $55 million upfront payment and a $55 million equity investment from Bristol Myers Squibb. Prime Medicine is also eligible to receive more than $3.5 billion in milestones,..."

"On the Effective Date, the Company entered into the Purchase Agreement with BMS, pursuant to which the Company agreed to issue and sell, and BMS agreed to purchase, in an unregistered offering (the “Offering”), 11,006,163 shares [...] for an aggregate purchase price of $55.0 million..."
👍️0
Monksdream Monksdream 4 meses hace
PRME new 52=week low
👍️0
wiwineguy wiwineguy 4 meses hace
K. I'm in!
👍️0
Monksdream Monksdream 4 meses hace
DAKT
👍️0
wiwineguy wiwineguy 4 meses hace
You are amazing Monk. Any recommendations
👍️0
Monksdream Monksdream 4 meses hace
PRME under $5
👍️0
Monksdream Monksdream 4 meses hace
PRME new 52 week low
👍️0
Monksdream Monksdream 5 meses hace
PRME under $6
👍️0
Monksdream Monksdream 6 meses hace
PRME under $10:
👍️0
Monksdream Monksdream 7 meses hace
Great post
Friday Cathie Wood bought more shares for her flagship Ark Fund (ARKK)
I think she has been buying on the decline
She isn’t particularly interested in how well or how lousy the management controls costs it’s the potential she believes exists
There are about a dozen, if not more, listed gene editing companies
Not all will make it before they run out of money and have to raise more operating capital
Notice the $2 to $4 bounces on the way to lower lows
👍️0
Monksdream Monksdream 7 meses hace
PRME under $10
👍️0
jondoeuk jondoeuk 7 meses hace
PRME vs Tome vs Tessera vs NTLA vs CRSP vs...!

They fact this article needs to be written could mean a legal battle is coming https://www.nature.com/articles/s41587-024-02208-0
👍️0
NY1972 NY1972 8 meses hace
This $500M company burns $200M a year. These PhDs have been spoiled by Wall St. when money was cheap. Who wants to be their sugar daddy?
👍️0
jondoeuk jondoeuk 8 meses hace
I'm sure in the (near) future they will (functionally) cure (rare) diseases, but not before they dilute a whole bunch more.
👍️0
jondoeuk jondoeuk 10 meses hace
The CEO has been contently telling investors how easy it would be to bring in funding through partnerships and how difficult capital markets are. Yet they did a secondary. He needs to go. Also, I don't think their IP is gatekeeping others.
👍️0

Su Consulta Reciente

NASDAQ
PRME
Prime Medicine
TG
IES
Intesa Sanpaolo
BOV
IBIT39
iShares Bitcoin Trust ETF
AQSE
BUR.GB
Burford Capital
BIT
WOEE
ETF
TSX
GH
Gamehost
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados